[Systemic therapy for malignant melanoma]. / Medikamentöse Therapie des malignen Melanoms.
Hautarzt
; 63(11): 885-98, 2012 Nov.
Article
en De
| MEDLINE
| ID: mdl-23114509
ABSTRACT
For decades dacarbazine was the standard in the therapy for metastatic melanoma even though response rates were low. In recent years multiple pharmacological approaches have led to new therapy options including immune modulators like anti-CTLA4 antibodies and kinase inhibitors of the MAPK signaling pathway that showed better response rates and increased overall survival. However, since immune modulators lead only in a small subgroup of patients to long-term responses and kinase inhibitors lose their function due to development of resistance after several months, continuation of clinical studies is strongly required. Classical chemotherapeutic drugs will remain a basic part of the therapy especially as combinations of different treatment options have to be focused on in order to achieve better long-term survival rates.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Terapia Molecular Dirigida
/
Factores Inmunológicos
/
Melanoma
/
Anticuerpos Monoclonales
/
Antineoplásicos
Límite:
Humans
Idioma:
De
Revista:
Hautarzt
Año:
2012
Tipo del documento:
Article